Can metagenomic next-generation sequencing identify the pathogens responsible for culture-negative prosthetic joint infection?

Wang, Chaoxin; Huang, Zida; Li, Wenbo; Fang, Xinyu; Zhang, Wenming

doi:10.1186/s12879-020-04955-2

Table 4 Treatment factors and results of the TA groups

From: Can metagenomic next-generation sequencing identify the pathogens responsible for culture-negative prosthetic joint infection?

Case	Tsukayama type	Surgical protocol	mNGS results	Intravenous antibiotic regimen		Oral antibiotic regimen	Reason for culture-negative result	Follow-up (month)	Subsequent intervention	Antibiotic costs (Yuan)
Case	Tsukayama type	Surgical protocol	mNGS results	Initial	Targeted	Oral antibiotic regimen	Reason for culture-negative result	Follow-up (month)	Subsequent intervention	Antibiotic costs (Yuan)
TA-1	IV	Two-stage revision	Staphylococcus aureus	Vancomycin Meropenem	Vancomycin	Levofloxacin Rifampicin	Prior use of antibiotics	24	–	11,146.6
TA-2	IV	Two-stage revision	Parvimonas micra	Vancomycin Imipenem	Amoxicillin Clavulanate	Amoxicillin/Clavulanate	Fastidious bacteria	23	–	10,421
TA-3	IV	Two-stage revision	Corynebacterium	Vancomycin Meropenem	Vancomycin	Levofloxacin Rifampicin	Prior use of antibiotics	32	–	16,661.04
TA-4	IV	Two-stage revision	Staphylococcus epidermidis	Vancomycin Ceftazidime	Vancomycin	Linezolid	Prior use of antibiotics	30	–	10,312.27
TA-5	II	I&D	Mycoplasma hominis	Vancomycin Meropenem	Levofloxacin	Doxycycline Levofloxacin	Fastidious bacteria	18	–	8391.27
TA-6	II	I&D	Mycoplasma hominis	Vancomycin Meropenem	Levofloxacin	Doxycycline Levofloxacin	Fastidious bacteria	27	–	8391.27
TA-7	II	One-stage revision	Streptococcus agalactiae	Vancomycin Ceftazidime	Ceftriaxone	Levofloxacin	Unknown	18	–	11,946.99
TA-8	IV	I&D	Staphylococcus epidermidis	Vancomycin Levofloxacin	Vancomycin	Moxifloxacin Rifampicin	Unknown	27	–	11,016.02
TA-9	IV	I&D	Mycoplasma hominis	Vancomycin Ceftazidime	Levofloxacin	Levofloxacin Doxycycline	Unknown	27	–	2959.54
TA-10	IV	I&D	Staphylococcus epidermidis	Vancomycin Tazocin	Vancomycin	Linezolid	Unknown	19	–	9298.5
TA-11	IV	Two-stage revision	Finegoldia magna	Vancomycin Meropenem	Vancomycin Tazocin	Amoxicillin Clavulanate	Fastidious bacteria	17	–	15,499.49
TA-12	IV	Two-stage revision	Candida tropicalis	Vancomycin	Fluconazole	Fluconazole	Fastidious bacteria	12	–	5925.74

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us